Abstract

Aims: Neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) are biomarkers for neuroaxonal damage. We assessed whether NfL and other biomarker levels in the CSF are correlated to the loss of presynaptic dopamine transporters in neurons as detected with dopamine transporter SPECT (DaTscan).Methods: We retrospectively identified 47 patients (17 Alzheimer’s dementia, 10 idiopathic Parkinson’s disease, 7 Lewy body dementia, 13 progressive supranuclear palsy or corticobasal degeneration) who received a DaTscan and a lumbar puncture. DaTscan imaging was performed according to current guidelines, and z-scores indicating the decrease in uptake were software based calculated for the nucleus caudatus and putamen. The CSF biomarkers progranulin, total-tau, alpha-synuclein, NfL, and pNfH were correlated with the z-scores.Results: DaTscan results in AD patients did not correlate with any biomarker. Subsuming every movement disorder with nigrostriatal neurodegeneration resulted in a strong correlation between putamen/nucleus caudatus and NfL (nucleus caudatus right p < 0.01, putamen right p < 0.05, left p < 0.05) and between pNfH and putamen (right p < 0.05; left p < 0.042). Subdividing in disease cohorts did not reveal significant correlations. Progranulin, alpha-synuclein, and total-tau did not correlate with DaTscan results.Conclusion: We show a strong correlation of NfL and pNfH with pathological changes in presynaptic dopamine transporter density in the putamen concomitant to nigrostriatal degeneration. This correlation might explain the reported correlation of impaired motor functions in PD and NfL as seen before, despite the pathological heterogeneity of these diseases.

Highlights

  • The diagnosis of a movement disorder (MD) is based on clinical symptoms (Balestrino and Schapira, 2020)

  • We divided the patients into two cohorts (AD and MD) and subcohorts according to clinical characteristics

  • When comparing Neurofilament light chain (NfL) levels from MD and Alzheimer’s disease (AD) patients to the control group, we could find a significant increase in patients with AD, MD, Lewy bodies (LBD), and progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD)

Read more

Summary

Introduction

The diagnosis of a movement disorder (MD) is based on clinical symptoms (Balestrino and Schapira, 2020). Movement disorders are histopathologically heterogeneous entities with the idiopathic Parkinson’s disease (PD) being the most common form. It involves the degeneration of dopaminergic neurons in the pars compacta of the substantia nigra, which inhibits the motor-inhibiting part of the striatum resulting in a nigro-striatal degeneration (Balestrino and Schapira, 2020). There are numerous biomarkers established mirroring general, neuronal, or neuroaxonal neurodegeneration, but so far, no biomarker is known that detects dopaminergic neurodegeneration nor proteinopathies caused by aggregated alpha-synuclein protein (Mollenhauer and Trenkwalder, 2009; Fayyad et al, 2019)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call